Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Phase II data presented on PEGylated therapy in previously treated metastatic breast cancer

Jan. 5, 2012

Tragara multikinase inhibitor may be beneficial to treat triple-negative breast cancer

Jan. 5, 2012

Interim data presented from phase I/II trial of neratinib plus capecitabine in breast cancer

Jan. 4, 2012

Phase II study investigates effects of ganetespib in subjects with breast cancer

Jan. 4, 2012

Mochida reports potent in vivo analgesic activity for proprietary drug

Jan. 3, 2012

Selective GlyT2 inhibitor shows promising analgesic effects in vivo

Jan. 3, 2012

Takeda identifies benzazepine derivatives for treatment of obesity

Jan. 3, 2012

Toray divulges new inhibitors of 11-beta-HSD1

Jan. 2, 2012

Astellas Pharma presents new drug for treatment of transplant rejection

Jan. 2, 2012

Findings presented from two phase III trials of Lu-AA-21004 in GAD

Jan. 2, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...